Tallinn-based medtech startup Nanordica Medical has secured €1.75 million in funding to bring its pioneering wound care products to market. Led by Specialist VC with participation from Superangel and Amalfi, the investment will support the launch of Nanordica’s advanced antibacterial dressings, designed to treat severe wounds more effectively. Combining copper and silver nanoparticles, their solution offers up to eight times better bacterial inactivation compared to traditional treatments, significantly improving healing times for conditions such as diabetic foot ulcers.
100M patients suffer from chronic wounds such as diabetic foot, venous leg and pressure ulcers. Moreover, the prevalence is increasing by 12% annually due to the ageing of the population and the increase in underlying diseases like diabetes and obesity. 1M amputations worldwide are caused annually by these wounds, and most of them are related to poorly managed bacterial infection of wounds.
Patients with infected wounds are typically treated with systemic antibiotics or traditional antibacterials such as silver ion-based dressings or ointments. The Nanordica Medical’s team discovered that by combining copper with silver nanoparticles, bacterial infection can be inactivated up to 8x better compared to traditional antibacterial solutions. Remarkably, the effect is achieved at very low concentrations, which is important because in this case antibacterial does not harm the patient’s skin cells. A randomized controlled trial of developed wound dressing carried out on 30 patients with infected diabetic foot ulcers showed improved safety and twice as fast healing as one of the most widely used competing silver ion-based wound dressing.
“We achieved a crucial milestone by demonstrating the safety and efficacy of our advanced wound dressing in patients with the most challenging wounds, diabetic foot ulcers“, stated co-founder and CEO of Nanordica Medical Olesja Bondarenko. “Our next goal is to get the product to the market and in the hands of patients.”
Nanordica Medical’s team is planning to confirm these exciting results in a larger trial. A multicentered study involving 170 patients with diabetic foot ulcers is planned to start in Q2 2024. This will be one of the largest studies of its kind, paving the path to the inclusion of Nanordica Medical’s wound care products into the reimbursement and treatment guidelines.
“Planned clinical trial will add valuable data for taking care of patients with diabetic foot ulcers”, stated Prof. Dr. José Luis Lázaro Martínez, the Chair of the Diabetic Foot Committee of European Wound Management Association and Coordinator / Principal Investigator of the multicentered trial.
“We were inspired by the extraordinary determination and resilience of Nanordica Medical’s founder team. The company’s innovative wound care solution has the potential to positively impact the lives of chronic wound patients across the world”, says Gerri Kodres, the Founder Partner of Specialist VC.
Nanordica Medical’s first product for veterinary use Ravimus Vet was launched in 2023, and the human product is planned to launch in 2025.
Click to read more funding news.
Read the orginal article: https://arcticstartup.com/nanordica-medical-raises-e1-75-million/
